durogesic smat 100 µg/h
janssen-cilag gmbh (8009839) - fentanyl - transdermales pflaster - teil 1 - transdermales pflaster; fentanyl (06903) 16,8 milligramm
durogesic smat 75 µg/h
janssen-cilag gmbh (8009839) - fentanyl - transdermales pflaster - teil 1 - transdermales pflaster; fentanyl (06903) 12,6 milligramm
durogesic smat 25 µg/h
janssen-cilag gmbh (8009839) - fentanyl - transdermales pflaster - teil 1 - transdermales pflaster; fentanyl (06903) 4,2 milligramm
sempera liquid 10 mg/ml
janssen-cilag gmbh (8009839) - itraconazol - lösung zum einnehmen - itraconazol (23401) 10 milligramm
imodium n 0,2 mg/ml lösung zum einnehmen
janssen-cilag gmbh (8009839) - loperamidhydrochlorid - lösung - teil 1 - lösung; loperamidhydrochlorid (11844) 0,2 milligramm
risperdal lösung 1mg/ml
janssen-cilag gmbh (8009839) - risperidon - lösung zum einnehmen - risperidon (24756) 1 milligramm
erypo fs 40 000 i.e./ml
janssen-cilag gmbh (8009839) - epoetin alfa - injektionslösung - teil 1 - injektionslösung; epoetin alfa (26243) 0,336 milligramm
haloperidol-janssen 1,0 mg gr
janssen-cilag gmbh (8009839) - haloperidol - tablette - teil 1 - tablette; haloperidol (00609) 1 milligramm
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
doribax
janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibiotika für den systemischen einsatz, - doribax ist indiziert für die behandlung folgender infektionen bei erwachsenen:nosokomiale pneumonie (einschließlich ventilator-assoziierten pneumonie);komplizierte intra-abdominale infektionen, komplizierte harnwegsinfektionen. es sollte erwogen werden, um die offiziellen richtlinien über den angemessenen gebrauch von antibakteriellen wirkstoffen.